US FDA Grants Priority Review to Zydus Therapeutics' Saroglitazar for Primary Biliary Cholangitis
Zydus Therapeutics, a subsidiary of Zydus Lifesciences Limited, has secured Priority Review designation from the US Food and Drug Administration for its New Drug Application for saroglitazar targeting primary biliary cholangitis (PBC). The drug is being evaluated for use alongside ursodeoxycholic acid (UDCA) in adult patients with insufficient response to UDCA alone, or as a standalone option for those unable to tolerate UDCA.
The regulatory body has set a Prescription Drug User Fee Act target decision date of November 27, 2026. Priority Review status accelerates FDA scrutiny of applications for medicines that could deliver meaningful advances in treating, diagnosing, or preventing serious medical conditions.
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, stated that the Priority Review acceptance underscores substantial therapeutic gaps for PBC patients and represents a significant milestone toward bringing saroglitazar to the American market. The company intends to work with the FDA during the review period while simultaneously developing its medical affairs and commercialization infrastructure, targeting a potential US market entry in the fourth quarter of fiscal year 2027.
The application rests on findings from the EPICS-III trial, a Phase 3 randomized, double-blind, placebo-controlled investigation of saroglitazar in PBC patients with inadequate UDCA response or intolerance. Results from this registrational study were presented as a late-breaking session at the European Association for the Study of the Liver Congress in Barcelona on May 30, 2026.
Raj Vuppalanchi, MD, a Professor of Medicine at Indiana University School of Medicine and Global Principal Investigator for EPICS-III, noted that the trial met its primary objective by demonstrating clinically significant biochemical improvements alongside a favorable safety profile.
In the 148-patient trial, saroglitazar achieved its primary endpoint at Week 52, showing statistically significant biochemical response gains relative to placebo. Treatment with saroglitazar resulted in biochemical response in 56.7% of participants compared to 9.8% receiving placebo, representing a 48% treatment differential (95% CI: 35.3, 60.8) (p < 0.001). Among patients with baseline alkaline phosphatase (ALP) levels at or below three times the upper limit of normal, response rates were 83.1% versus 14.7%, respectively.
Biochemical response was defined as achieving all of the following at 12 months: ALP below 1.67 times the upper limit of normal, at least 15% ALP reduction from baseline, and total bilirubin at or below the upper limit of normal, or direct bilirubin at or below the upper limit of normal in patients with known Gilbert's syndrome.
Baseline mean ALP levels differed between groups, with saroglitazar recipients averaging 363 U/L compared to 317.2 U/L in the placebo arm. By Week 52, saroglitazar produced a treatment difference of -124.1 U/L (-40.1%) in least-squares mean ALP change from baseline. Patients on saroglitazar experienced a -115.4 U/L (-33.5%) reduction from baseline, whereas those on placebo saw a +8.8 U/L (+6.5%) increase.
Dr. Kris Kowdley, Director of the Liver Institute Northwest and Professor at Washington State University's Elson S. Floyd College of Medicine, characterized the biochemical response separation as clinically meaningful for patients experiencing disease progression despite UDCA therapy. He emphasized that substantial ALP reductions represent an important therapeutic objective in PBC, as ALP functions as a predictive marker for long-term clinical trajectories. The findings suggest saroglitazar could serve as a valuable therapeutic alternative for patients with suboptimal UDCA responses and persistently elevated ALP levels.
As a secondary outcome, Week 24 assessments revealed that saroglitazar recipients experienced statistically significant pruritus reduction compared to placebo, with 5-D Itch Total score changes of -5.9 versus -2.7, yielding a treatment difference of -3.2 (95% CI: -5.66, -0.82) (p = 0.009). By Week 52, both groups showed comparable improvements, with saroglitazar-treated patients experiencing a -4.6 change and placebo recipients a -4.4 change, which did not reach statistical significance.
Saroglitazar demonstrated favorable tolerability throughout the EPICS-III trial. The majority of treatment-emergent adverse events were classified as mild to moderate. Serious adverse events occurred in 6.3% of the saroglitazar group versus 11.1% of the placebo group. Investigators attributed none to study medication, and no treatment-related deaths were documented. Adverse events appearing in more than 5% of participants and at least 2% more frequently with saroglitazar than placebo included headache, hypertension, upper respiratory tract infection, abdominal pain, COVID-19, diarrhea, and vitamin D deficiency.
Compare options


